Therefore, we wish to develop a nanoparticle formulation modified with tumor-targeting single-chain antibody fragment (scFv) for systemic delivery of siRNA-ENO1 in the future [43], which may make it possible that ENO1 serves as a molecular therapeutic target for NSCLC treatment. The gene discussed is ENO1; the disease is neoplasm.